Inicio>>Signaling Pathways>> Microbiology & Virology>> Influenza virus>>2'-Deoxy-2'-fluorocytidine

2'-Deoxy-2'-fluorocytidine

Catalog No.GC61756

La 2'-desoxi-2'-fluorocitidina, un anÁlogo de nucleÓsido, es un potente inhibidor de la replicaciÓn del virus de la fiebre hemorrÁgica de Crimea-Congo (CCHFV).

Products are for research use only. Not for human use. We do not sell to patients.

2'-Deoxy-2'-fluorocytidine Chemical Structure

Cas No.: 10212-20-1

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL Water)
52,00 $
Disponible
100 mg
46,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

2'-Deoxy-2'-fluorocytidine, an nucleoside analog, is a potent inhibitor of Crimean-Congo hemorrhagic fever virus (CCHFV) replication. 2′-deoxy-2′-fluorocytidine can act synergistically with T705 to increase the potency of both compounds antiviral effects on CCHFV replication[1].

2'-Deoxy-2'-fluorocytidine has antiviral activities, showing 50% effective concentrations (EC50) of 61 nM and 31 nM against CCHFV and CCHFV/ZsG in Huh7 cells, respectively. And it shows a 50% cytotoxicity concentration (CC50) of >50.0 μM in Huh7 cells[1].

[1]. Stephen R Welch, et al. Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antiviral Res. 2017 Nov;147:91-99.

Reseñas

Review for 2'-Deoxy-2'-fluorocytidine

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2'-Deoxy-2'-fluorocytidine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.